Business
Axovant update on 2nd cohort of SUNRISE-PD trial
Axovant update on 2nd cohort of SUNRISE-PD trial.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 2646B\n Oxford Biomedica PLC\n 06 October 2020\n \n \n \n \n \n \n \n \n \n \n Oxford Biomedica notes Axovant's positive six-month follow-up from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD\n \n \n \n \n \n \n \n \n Oxford, UK - 6 October, 2020: Oxford Biomedica plc (LSE:OXB) (\"Oxford Biomedica\" or \"the Group\"), a leading gene and cell therapy group, notes Axovant Gene Therapies' (\"Axovant\") positive six-month follow-up data from the second cohort of the SUNRISE-PD Phase 2 trial of AXO-Lenti-PD gene therapy in Parkinson's disease.\n \n Key highlights from the follow-up data were as follows:\n \n \n · AXO-Lenti-PD was well-tolerated with no treatment-related serious adverse events at 6 months\n \n · 21-point mean improvement in UPDRS Part III \"OFF\" score, a 40% improvement from baseline based on the two evaluable patients in the study, exceeding predefined criteria for success\n \n · Greater than 2-hour improvement from baseline in both diary \"good ON time\" and diary OFF time assessments\n \n · EXPLORE-PD, a randomised, sham-controlled study of AXO-Lenti-PD is expected to begin dosing in 2021\n \n To view the full announcement from Axovant, please follow this link: (LINK)\n \n \n In June 2018, Oxford Biomedica out-licenced OXB-102 (later renamed AXO-Lenti-PD) to Axovant through a $842.5 million worldwide licence agreement (LINK). In July 2020 a three year clinical supply agreement was additionally signed with Axovant to manufacture GMP batches to support the ongoing and future clinical development of AXO-Lenti-PD (LINK).\n \n \n \n \n \n \n \n \n -Ends-\n \n \n \n \n \n \n \n \n \n Enquiries:\n \n \n \n \n \n \n \n \n Oxford Biomedica plc\n \n John Dawson, Chief Executive Officer\n Stuart Paynter, Chief Financial Officer\n Catherine Isted, Head of Corporate Development & IR\n \n \n \n \n \n \n \n T: +44 (0)1865 783 000\n \n \n T: +44 (0)1865 783 000\n \n \n T: +44 (0)1865 954 161 / E: [email protected]\n \n \n \n \n \n \n \n \n \n \n \n Consilium Strategic Communications\n \n Mary-Jane Elliott/Matthew Neal\n \n \n \n \n \n T: +44 (0)20 3709 5700\n \n \n \n \n \n \n \n \n \n \n ...